Mabpharm Limited (2181) Stock Statistics & Valuation Metrics

Mabpharm Limited has a market cap or net worth of HK$2.06B. The enterprise value is ―.

Mabpharm Limited has 4,124,080,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Mabpharm Limited’s return on equity (ROE) is -1.44 and return on invested capital (ROIC) is -14.93%.

The current PE Ratio of Mabpharm Limited is -8.48. Mabpharm Limited’s PEG ratio is -0.23.

In the last 12 months, Mabpharm Limited had revenue of 258.23M and earned -127.95M in profits. Earnings per share was -0.03.

In the last 12 months, operating cash flow was -64.18M and capital expenditures -12.63M, giving a free cash flow of -76.81M billion.

Mabpharm Limited pays an annual dividend of ―, resulting in a dividend yield of ―

Mabpharm Limited upcoming earnings date is Aug 27, 2025, TBA Not Confirmed.

Mabpharm Limited as a current ratio of 1.17, with Debt / Equity ratio of 329.56%

In the past 12 months, Mabpharm Limited has paid 0.00 in taxes.

Mabpharm Limited EV to EBITDA ratio is -19.00, with an EV/FCF ratio of -20.26.

Mabpharm Limited has HK$89.34M in cash and marketable securities with ¥293.09M in debt, giving a net cash position of HK$203.75M billion.

Gross margin is 84.96%, with operating margin of -46.34%, and net profit margin of -49.55%.

The average price target for Mabpharm Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―